EsoCap successfully closes a private financing round, with investments from existing and new investors The new funding was facilitated by EsoCap benefitting from a unique programme implemented by the Canton…

Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101 ESO-101, EsoCap’s lead product candidate, consists of a capsule with a rolled, thin…

EsoCap’s targeted application technology drastically increases mucosal contact time and enables effective local treatment of various esophageal diseases for the first time Proof of principle in human established; Phase II…

The feature in the latest issue of the renowned Nature Research publication gives an insightful overview of EsoCap’s company profile and the current development stage of their novel platform technology…

EsoCap announced today that the novelty of their unique drug delivery technology has once again been confirmed by a patent, granted by the State of Israel, under number 252893, based…

EsoCap AG today announced the issue, by the Patent and Trademark Office, of a patent in Australia under no. 2015371725, based on patent application no. 2017132866/04 (057778). The patent is…

EsoCap AG hosted a well-attended virtual Investigators’ Meeting for the ACESO study on March 18, 2021. ACESO is a randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of…

EsoCap AG organized a scientific advisory board meeting with eleven international experts in Eosinophilic Esophagitis (EoE) in a digital format on December 1, 2020. Three distinguished experts gave keynote presentations…

EsoCap AG has announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,744,095 on August 18, 2020. The patent is directed at the smart application…